Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AEterna Zentaris
With
Dana-Farber Cancer Institute
A pre-planned interim analysis is expected to take place in Q1 of 2013.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient was previously diagnosed with multiple myeloma based on standard diagnostic criteria.
Patients must have relapsed (progressed \> 60 days) after their last dose of bortezomib-based therapy. In addition, patients may be relapsed or refractory to other non-bortezomib-based therapies.
Patient has received at least 1 but not more than 4 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen.
Patients must have adequate organ and marrow function.
You may not be if
Patients must not be refractory to any bortezomib-containing regimen.
History of allergic reactions or intolerance attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine), bortezomib or dexamethasone or any of their components.
Prior treatment with perifosine or an investigational proteasome inhibitor.
Chemotherapy or other therapy experimental or proven that is or may be active against myeloma within two weeks (14 days) prior to Cycle 1 Day 1.
Clareo Health | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
